Impact of Arterial Hypertension and Use of Antihypertensive Pharmacotherapy on Mortality in Patients Hospitalized due to COVID-19: The CRACoV-HHS Study.
Wiktoria WojciechowskaMichał TerleckiMarek KlocekAgnieszka PacAgnieszka OlszaneckaKatarzyna Stolarz-SkrzypekMarek JastrzebskiPiotr JankowskiAleksandra OstrowskaTomasz DrożdżAleksander PrejbiszPiotr DobrowolskiAndrzej JanuszewiczMarcin KrzanowskiMaciej T MałeckiTomasz GrodzickiReinhold KreutzMarek W Rajzernull nullPublished in: Hypertension (Dallas, Tex. : 1979) (2022)
Although the diagnosis of preexisting hypertension per se had no significant impact on in-hospital mortality among patients with COVID-19, treatment with any first-line blood pressure-lowering drug had a profound beneficial effect on survival in patients with hypertension. These data support the need for antihypertensive pharmacological treatment during the COVID-19 pandemic.
Keyphrases
- blood pressure
- arterial hypertension
- hypertensive patients
- heart rate
- end stage renal disease
- coronavirus disease
- sars cov
- chronic kidney disease
- ejection fraction
- newly diagnosed
- emergency department
- prognostic factors
- type diabetes
- cardiovascular disease
- metabolic syndrome
- electronic health record
- skeletal muscle
- autism spectrum disorder
- respiratory syndrome coronavirus
- replacement therapy
- artificial intelligence
- data analysis
- patient reported